检索结果-南通市图书馆

Military Medical Research 2022年第6期9卷 754-756页

作者： Jiang-Yi Wang guo-Peng Yu Long Li guo-wen lin Ding-Wei Ye Department of Urology Fudan University Shanghai Cancer Center270 Dong'an RoadShanghai 200032China Department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032China Department of Urology Shanghai Ninth People's HospitalShanghai Jiaotong University School of MedicineShanghai 200011China

Dear Editor,Although the incidence of prostate cancer(PCa) has decreased in recent decades in Western countries, it has gradually increased in China due to the increasingly longer life expectancy and more popular west... 详细信息

关键词： Metastatic castration-resistant prostate cancer PSA decline PSA velocity Overall survival Time to PSA progression

External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort

在线全文

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2012年第5期14卷 738-744页

作者： Yao Zhu Jin-You Wang Yi-Jun Shen Bo Dai Chun-Guang Ma wen-Jun Xiao guo-wen lin Xu-Dong Yao Shi-lin Zhang Ding-Wei Ye Department of Urology Fudan University Shanghai Cancer Center Shanghai 200032 China Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 China

Several prediction models have been developed to estimate the outcomes of prostate biopsies. Most of these tools were designed for use with Western populations and have not been validated across different ethnic groups. Therefore, we evaluated the predictive value of the Prostate Cancer Prevention Trial （PCPT） and the European Randomized Study of Screening for Prostate Cancer （ERSPC） risk calculators in a Chinese cohort. Clinicopathological information was obtained from 495 Chinese men who had undergone extended prostate biopsies between January 2009 and March 2011. The estimated probabilities of prostate cancer and high-grade disease （Gleason 〉6） were calculated using the PCPT and ERSPC risk calculators. Overall measures, discrimination, calibration and clinical usefulness were assessed for the model evaluation. Of these patients, 28.7% were diagnosed with prostate cancer and 19.4% had high-grade disease. Compared to the PCPT model and the prostate-specific antigen （PSA） threshold of 4 ng m1-1, the ERSPC risk calculator exhibited better discriminative ability for predicting positive biopsies and high-grade disease （the area under the curve was 0.831 and 0.852, respectively, P〈O.01 for both）. Decision curve analysis also suggested the favourable clinical utility of the ERSPC calculator in the validation dataset. Both prediction models demonstrated miscalibration： the risk of prostate cancer and high-grade disease was overestimated by approximately 20% for a wide range of predicted probabilities. In conclusion, the ERSPC risk calculator outperformed both the PCPT model and the PSA threshold of 4 ng ml- z in predicting prostate cancer and high-grade disease in Chinese patients. However, the prediction tools derived from Western men significantly overestimated the probability of prostate cancer and high-grade disease compared to the outcomes of biopsies in a Chinese cohort.

关键词： European Randomized Study of Screening for Prostate Cancer (ERSPC) predictive value of tests prostate cancer prostate-specific antigen (PSA) Prostate Cancer Prevention Trial (PCPT)

Clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2019年第2期21卷 131-136页

作者： guo-wen lin Gao-Xiang Li Bo Dai Ding-Wei Ye Yun-Yi Kong Yue Wang Yi-Jun Shen Department of Urology Fudan University Shanghai Cancer CenterShanghai 20032China Department of Oncology Fudan University Shanghai Medical CollegeShanghai 200032China Department of Pathology Fudan University Shanghai Cancer CenterShanghai 200032China

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castratio n-resista nt prostate can cer(mCRPC).A total of 146 patie nts with docetaxel-naive group(103 cases)and docetaxel-resista nt group(43 cases)were en rolled from the Sha nghai Cancer Center(Sha nghai,Chin a)in this retrospective cohort *** efficacy endpoints were prostate-specific antigen response rate,prostate-specific antigen progress!on-free survival,clinical/radiographic progression-free survival,and overall survival in response to abiraterone plus *** higher prostate-specific antigen response rate was found in docetaxel-naive group(54.4%,56/103)compared to docetaxel-resistant group(34.9%,15/43)(P=0.047).In addition,significantly higher median prostate-specific antigen progress!on-free survival(14.0 vs 7.7 months,P=0.005),clinical or radiographic progression-free survival(17.0 vs 12.5 months,P=0.003),and overall survival(27.0 vs 18.0 mon ths,P=0.016)were found in docetaxel-naTve group compared to docetaxel-resistant group,*** univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall *** sum up,our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naTve and docetaxel-resistant Chinese ***,higher PSA response rate and longer overall survival were observed in the docetaxel-naTve group,which suggested that abiraterone was more effective for docetaxel-naive patients than for docetaxel failures.

关键词： abiraterone acetate castration-resistant prostate cancer clinical activity docetaxel-naive docetaxel-pretreated

The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer： who can benefit from ketoconazole therapy？

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2012年第5期14卷 732-737页

作者： guo-wen lin Xu-Dong Yao Ding-Wei Ye Yao Zhu Shi-lin Zhang Bo Dai Hai-Liang Zhang Yi-Jun Shen Chun-Guang Ma Department of Urology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032China

We investigated the prognostic value of some variables of effective ketoconazole treatment for metastatic castration-resistant prostate cancer （mCRPC）. In total, 163 patients with mCRPC were eligible, receiving ketoconazole 200-400 mg three times daily with replacement doses of prednisone. Progression-free survival （PFS） was calculated from the beginning of the ketoconazole therapy to the onset of disease progression. The prognostic value of different variables for PFS was assessed by Cox regression analysis. The median PFS was 2.6 months （0.5-8.6 months） for these patients. The serum testosterone level changed during therapy, which decreased when the prostate-specific antigen （PSA） declined; the serum testosterone level increased as the levels of PSA relapsed. The median PFS values for patients associated with different factors were the following： 1.4 and 3.5 months for a nadir PSA of ≥ 0.2 and 〈0.2 ng ml- 1, respectively （hazard rate （HR）=4.767, P〈0.001）; 3.1 and 1.6 months for a baseline testosterone of ≥0.1 and 〈0.1 ng m1-1, respectively （HR=2.865, P=0.012）; 2.8 and 1.9 months for a baseline haemoglobin of ≥ 120 and 〈120 g 1-1, respectively （HR= 1.605, P〈0.001）; and 3.0 and 1.9 months for a PSA doubling time （PSADT） of ≥ 2.0 and 〈2.0 months, respectively （HR= 1.454, P=-0.017）. A risk model was constructed according to the four factors that divided patients into three subgroups of low risk （0-1 factors）, moderate risk （2 factors） and high risk （3-4 factors） with PFS values of 3.6, 3.0 and 1.4 months, respectively （HR=1.619, P〈0.001）. A nadir PSA of ≥0.2 ng m1-1, a baseline testosterone of 〈0.1 ng m1-1, a baseline haemoglobin of 〈 120 g I- 1 and a PSADT of 〈2 months were associated with a poor PFS. This risk model could provide evidence to predict the survival benefit of ketoconazole therapy.

关键词： castration-resistant prostate cancer ketoconazole therapy predictor progression-free survival

Prostate-specific antigen half-life： a new predictor of progression- free survival and overall survival in Chinese prostate cancer patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2009年第4期11卷 443-450页

作者： guo-wen lin Xu-Dong Yao Shi-lin Zhang Bo Dai Chun-Guang Ma Hai-Liang Zhang Yi-Jun Shen Yao Zhu Yi-Ping Zhu guo-Hai Shi Xiao-Jian Qin Ding-Wei Ye Department of Urology Cancer Hospital Fudan University Shanghai 200032 China Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 China

We investigated the potential value of prostate-specific antigen half-life （PSAHL） and decreasing velocity （PSAVd） to predict progression-free survival （PFS） and overall survival （OS） in Chinese patients with prostate cancer. A total of 153 patients treated with hormonal therapy were included in the study. Of these, 78 patients progressed to hormone- refractory prostate cancer （HRPC） and 24 patients died by the end of follow-up. PSAHL was defined as the time during which prostate-specific antigen （PSA） concentration became half of the initial value during the first hormonal therapy. PSAVd reflected the decreasing velocity of PSA during the first hormonal therapy. PFS was defined as the interval from the beginning of hormonal therapy to HRPC. Cox proportional hazards regression analysis was used to evaluate whether PSAHL and PSAVd were significantly associated with PFS and OS. The median PSAHL and PSAVd were 0.50 months and 33.8 ng mL^-1 per month. The median PFS and OS were 22.7 months （95% confidence interval [CI], 22.0-29.6 months） and 43.5 months （95% CI, 37.9-48.4 months）, respectively. On univariate and multivariate analysis, long PSAHL （〉 0.5 months）, metastatic disease, high biopsy Gleason scores （〉 8） and high nadir PSA （〉 0.4 ng mL^-1） were all found to be significantly associated with short PFS. Long PSAHL, high nadir PSA and short PSA doubling time （PSADT 〈 2.0 months） were significantly associated with short OS. There were no significant relationships between PSAVd and either PFS or OS. Thus, PSAHL is a promising new independent predictor of survival. Patients with long PSAHL were identified as those at high risk for a relatively short PFS and OS.

关键词： predictor prognosis prostate cancer prostate-specific antigen decreasing velocity prostate-specific antigen half-life

External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Asian Journal of Andrology 2018年第2期20卷 184-188页

作者： Yun-Jie Yang guo-wen lin Gao-Xiang Li Bo Dai Ding-Wei Ye Jun-Long Wu Hu-Yang Xie Yao Zhu Department of Urology Fudan University Shanghai Cancer Center Shanghai 200032 China Department of Oncology Shanghai Medical College Fudan University Shanghai 200032 China

Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer （CRPC）; however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for risk classification, although its utility for the chemotherapy-naive group is unclear. This study aimed to externally validate the Chi model and develop a new nomogram to predict overall survival （OS）. We retrospectively analyzed a cohort of 110 patients. Patients were distributed among good-, intermediate-, and poor-risk groups, according to the Chi model. The good-, intermediate-, and poor-risk groups had a sample size of 59 （53.6%）, 34 （30.9%）, and 17 （15.5%） in our dataset, and a median OS of 48.4, 29.1, and 10.5 months, respectively. The C-index of external validation of Chi model was 0.726. Univariate and multivariate analyses identified low hemoglobin concentrations （〈110 g l^-1）, liver metastasis, and a short time interval from androgen deprivation therapy to abiraterone initiation （〈36 months） as predictors of OS. Accordingly, a new nomogram was developed with a C-index equal to 0.757 （95% CI, 0.678-0.836）. In conclusion, the Chi model predicted the prognosis of abiraterone-treated, chemotherapy-naive patients with mCRPC, and we developed a new nomogram to predict the overall survival of this group of patients with less parameters.

关键词： abiraterone acetate castration-resistant prostate cancer external validation nomogram surviva

华北克拉通北部14亿年前古风化壳的地球化学特征及古气候意义

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

现代地质 2014年第2期28卷 243-255页

作者：郭文琳苏文博中国地质大学(北京)地球科学与资源学院

最近在河北涞水紫石口剖面的中元古界铁岭组-下马岭组界线（～1400 Ma）附近，发现了一套保存完好的碳酸盐岩古风化壳。野外观测和岩石矿物学研究显示，该古风化壳的岩性以含褐铁矿的铁质泥岩和伊利石粘土岩为主。相对上地壳平均化学组... 详细信息

最近在河北涞水紫石口剖面的中元古界铁岭组-下马岭组界线（～1400 Ma）附近，发现了一套保存完好的碳酸盐岩古风化壳。野外观测和岩石矿物学研究显示，该古风化壳的岩性以含褐铁矿的铁质泥岩和伊利石粘土岩为主。相对上地壳平均化学组分来说，古风化壳的主量元素氧化物中Al2 O3、TiO2、Fe2 O3和K2 O富集，SiO2轻微亏损，CaO、MgO和Na2 O强烈亏损；微量元素中Sc、Cu、Ga、Zr、Hf、Nb、Ta、In、Th、Li、V、Zn、Rb、Cs、W、Pb、U、Mo和Bi等化学性质稳定或易吸附于粘土中的元素含量接近上地壳平均化学组分值或呈不同程度富集，易溶元素Cr、Sr和Cd相对亏损；稀土元素全部富集，轻稀土元素与重稀土元素分异程度大，Ce正异常，Eu负异常。U/Th、Fe3＋/Fe2＋、Ce的正异常、化学蚀变指数与风化淋滤指数等多种指标都指示该古风化壳是在强氧化的中等到强烈的风化淋滤程度条件下形成。上述研究表明，在中元古代盖层纪（Calymmian Period，1600～1400 Ma）与延展纪（Ectasian Period，1400～1200 Ma）之交，剖面所在的华北克拉通北部应属于温暖湿润的热带-亚热带气候。

关键词：古风化壳古气候中元古代华北克拉通

在线全文

学校读者我要写书评

暂无评论

依地普仑片健康人体的药动学考察

中国医院药学杂志 2005年第10期25卷 925-927页

作者：温预关马崔温国林广州市脑科医院国家药品临床研究基地广东广州510370 北京艾斯克医药技术开发有限公司北京10012

目的:研究国产依地普仑片在健康人体内的药动学。方法:11名健康志愿者单剂量口服10mg依地普仑片,采用高效液相色谱法测定血浆中依地普仑浓度,并用3P97软件统计处理。结果:依地普仑药-时曲线符合二室模型,其Cmax,Tmax,t1/2,AUC0-132,AUC0... 详细信息

目的:研究国产依地普仑片在健康人体内的药动学。方法:11名健康志愿者单剂量口服10mg依地普仑片,采用高效液相色谱法测定血浆中依地普仑浓度,并用3P97软件统计处理。结果:依地普仑药-时曲线符合二室模型,其Cmax,Tmax,t1/2,AUC0-132,AUC0-∞分别为(16.8±2.4)μg.L-1,(3.3±0.6)h,(38.8±8.1)h,(605.2±150.8)μg.L-1.h,(660.4±159.1)μg.L-1.h。结论:为临床用药提供参考资料。

关键词：依地普仑片高效液相色谱法药动学

在线全文

学校读者我要写书评

暂无评论

不可控整流电路故障信号仿真分析

计算机仿真 2018年第10期35卷 477-480页

作者：郭文炎林真福建农林大学金山学院福建福州350002

为了降低故障信号对设备及人身安全造成的危害,需要对故障信号分析方法进行研究。采用当前分析方法对不可控整流电路中的故障信号进行分析时,存在抗干扰性能差和分析结果准确率低的问题。提出一种不可控整流电路故障信号分析方法,采用... 详细信息

为了降低故障信号对设备及人身安全造成的危害,需要对故障信号分析方法进行研究。采用当前分析方法对不可控整流电路中的故障信号进行分析时,存在抗干扰性能差和分析结果准确率低的问题。提出一种不可控整流电路故障信号分析方法,采用经验模式分解方法对电路中的信号进行筛选,将信号分解成频率不同的本征模式分量;对分解后的信号进行Hilbert变换,得到本征模式分量的瞬时频率,根据瞬时频率得到Hilbert谱对信号的幅值和频率进行计算,通过信号的边际谱对故障信号在不可控整流电路中的真实频率进行分析。采用多分辨分析框架的Mallat算法对故障信号进行分析识别,完成不可控整流电路的故障信号分析。仿真结果表明,所提方法的抗干扰性能强、分析结果准确率高。

关键词：不可控整流电路故障信号分析

Prediction and stratification for the surgical adverse events after minimally invasive esophagectomy:A two-center retrospective study

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2025年第3期31卷 50-61页

作者： Qi-Hong Zhong Jiang-Shan Huang Fei-Long guo Jing-Yu Wu Mao-Xiu Yuan Jia-Fu Zhu wen-Wei lin Sui Chen Zhen-Yang Zhang Jiang-Bo lin Department of Thoracic Surgery Fujian Medical University Union HospitalFuzhou 350001Fujian ProvinceChina The Graduate School Fujian Medical UniversityFuzhou 350001Fujian ProvinceChina Department of Thoracic Surgery Affiliated Hospital of Jinggangshan UniversityJi’an 343000Jiangxi ProvinceChina

BACKGROUND Minimally invasive esophagectomy(MIE)is a widely accepted treatment for esophageal cancer,yet it is associated with a significant risk of surgical adverse events(SAEs),which can compromise patient recovery and long-term *** preoperative identification of high-risk patients is critical for improving *** To establish and validate a risk prediction and stratification model for the risk of SAEs in patients with *** This retrospective study included 747 patients who underwent MIE at two centers from January 2019 to February *** were separated into a train set(n=549)and a validation set(n=198).After screening by least absolute shrinkage and selection operator regression,multivariate logistic regression analyzed clinical and intraoperative variables to identify independent risk factors for SAEs.A risk stratification model was constructed and validated to predict the probability of *** SAEs occurred in 10.2%of patients in train set and 13.6%in the validation *** with SAE had significantly higher complication rate and a longer hospital stay after *** key independent risk factors identified included chronic obstructive pulmonary disease,a history of alcohol consumption,low forced expiratory volume in the first second,and low albumin *** stratification model has excellent prediction accuracy,with an area under the curve of 0.889 for the training set and an area under the curve of 0.793 for the validation *** The developed risk stratification model effectively predicts the risk of SAEs in patients undergoing MIE,facilitating targeted preoperative interventions and improving perioperative management.

关键词： Surgical adverse events Minimally invasive esophagectomy Esophageal cancer Stratification model Perioperative management